Study of GT-220F for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This study tests an experimental drug called GT-220F in men with advanced prostate cancer that has stopped responding to hormone therapy. The goal is to see if the drug is safe and effective, and to find the best dose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 or older.
- Your prostate cancer has spread or come back despite treatment with drugs like enzalutamide, apalutamide, darolutamide, or abiraterone.
- You are currently on hormone therapy (ADT) that keeps your testosterone level low (under 50 ng/dL).
- Your cancer has shown signs of progression, either on scans or through rising PSA levels (at least two rises, with a first value of 2 ng/mL or higher).
- You have recovered from side effects of previous treatments, and your major organs (like bone marrow, liver, and kidneys) are working well enough.
- You need to have a heart function test showing your heart pumps at least 50% blood per beat, and you have no serious heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new radioactive treatment, [225Ac]Ac-FL-020, for men with metastatic castration-resistant prostate cancer (mCRPC) that has gotten worse despite other treatments. It's for those who have had at least one prior hormone therapy or chemotherapy.
This trial tests a new drug called FG-3246, which targets a protein (CD46) on prostate cancer cells. It's for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy, and who have had limited prior treatments.
This trial tests a new drug called KTX-2001, possibly combined with another drug (darolutamide), for men whose prostate cancer has spread and stopped responding to standard hormone treatments. The goal is to see if it can help shrink tumors or slow the cancer's growth.
This study tests an experimental drug for men whose prostate cancer has spread and stopped responding to standard hormone therapies. It may be an option if your PSA is rising despite treatment with drugs like enzalutamide or abiraterone.
This trial tests an extended treatment with a radioactive drug (177Lu-PSMA-617) to see how the body handles it, how safe it is, and how well it works. It is for men with metastatic castration-resistant prostate cancer who have not had chemotherapy yet.
This early-phase study tests whether REGN4336 is safe and how well it works, by itself or with REGN5678, in adults with advanced prostate cancer. It may help people whose cancer has continued to worsen despite standard prostate cancer medicines.
Hear when a new Metastatic Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.